|
Laxman Pai, Opalesque Asia: American alternative investment firm Ampersand Capital Partners announced the closing of the firm's latest fund with $1.2 billion in limited partner commitments.
Ampersand 2022 (AMP-22), which is Ampersand's eleventh primary fund since 1992, was significantly oversubscribed and held a single close less than three months after launch, said the private equity firm specializing in growth equity investments in the life sciences and healthcare sectors.
"Ampersand secured commitments from a diversified and global set of institutional investors including endowments, foundations, pension plans, insurance companies, funds of funds, and family offices," said a press release from the Boston-based middle-market PE firm.
Ampersand Managing Partner, Herb Hooper, said: "We greatly appreciate the strong support from both existing and new investors and their confidence in Ampersand's specialized Industrial Healthcare investment strategy which focuses on mission-critical tools and services supporting innovation in healthcare and life sciences."
According to the company, for more than 30 years, Ampersand has been a trusted partner to founders and CEOs, helping to accelerate growth and build numerous market-leading companies across the firm's core healthcare sectors.
"With this new fund, Ampersand intends to continue the firm's strategy of partnering with great entrepreneurs within our core sectors through both majority and mino...................... To view our full article Click here
|
RSS
